Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that an independent Data Monitoring Committee (DMC) has recommended continuing the pivotal Phase 3 RAISE trial evaluating intravenous (IV) ganaxolone for the treatment of refractory status epilepticus (RSE) following an interim analysis.

Creates strong position in security, audio visual, and smart living technology distribution for residential and commercial markets Highly complementary capabilities offer professional integrators an expanded selection of proprietary products, extensive third-party supplier relationships, and proven omni-channel reach Enhances Resideo's growth and margin profile and accretive to non-GAAP EPS in first full year of ownership Identified expected annual run-rate business and financial synergies of $75 million by year three $500 million perpetual convertible preferred equity investment from CD&R SCOTTSDALE, Ariz. and CHARLOTTE, N.C., April 15, 2024 /PRNewswire/ -- Resideo Technologies, Inc. (NYSE: REZI), a leading manufacturer and distributor of technology-driven products ...

The U.S. Orphan Drug Act is intended to assist and encourage companies to develop safe and effective therapies for the treatment of rare diseases and disorders, defined as one that affects fewer than 200,000 people in the U.S. In addition to providing a seven-year term of market exclusivity upon final FDA approval, orphan drug designation also positions Soligenix to be able to leverage a wide range of financial and regulatory benefits, including government grants for conducting clinical trials, waiver of expensive FDA user fees for the potential submission of a Biologics License Application (BLA), and certain tax credits.

LuxUrban Hotels Inc. (or the “Company”) (Nasdaq: LUXH, LUXHP), a hospitality company which leases entire existing hotels on a long-term basis and rents rooms in its hotels to business and vacation travelers, including through its partnership with Wyndham Hotels & Resorts (“Wyndham”), today announced financial results for full year (“FY 2023”) ended December 31, 2023, including EBITDA and adjusted EBITDA, which are non-GAAP measures and are accompanied by reconciliation tables in this release. The Company also announced that it filed its Form 10-K with the Securities and Exchange Commission on April 15, 2024.